GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group AS (OCSE:PEG) » Definitions » Quick Ratio

Pharma Equity Group AS (OCSE:PEG) Quick Ratio : 7.57 (As of Dec. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group AS Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Pharma Equity Group AS's quick ratio for the quarter that ended in Dec. 2024 was 7.57.

Pharma Equity Group AS has a quick ratio of 7.57. It generally indicates good short-term financial strength.

The historical rank and industry rank for Pharma Equity Group AS's Quick Ratio or its related term are showing as below:

OCSE:PEG' s Quick Ratio Range Over the Past 10 Years
Min: 0.01   Med: 4.34   Max: 71.38
Current: 7.57

During the past 13 years, Pharma Equity Group AS's highest Quick Ratio was 71.38. The lowest was 0.01. And the median was 4.34.

OCSE:PEG's Quick Ratio is ranked better than
74.75% of 1497 companies
in the Biotechnology industry
Industry Median: 3.41 vs OCSE:PEG: 7.57

Pharma Equity Group AS Quick Ratio Historical Data

The historical data trend for Pharma Equity Group AS's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group AS Quick Ratio Chart

Pharma Equity Group AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 2.84 1.96 7.57

Pharma Equity Group AS Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.96 2.09 1.92 1.60 7.57

Competitive Comparison of Pharma Equity Group AS's Quick Ratio

For the Biotechnology subindustry, Pharma Equity Group AS's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group AS's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group AS's Quick Ratio falls into.


;
;

Pharma Equity Group AS Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Pharma Equity Group AS's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Quick Ratio (A: Dec. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(65.335-0)/8.631
=7.57

Pharma Equity Group AS's Quick Ratio for the quarter that ended in Dec. 2024 is calculated as

Quick Ratio (Q: Dec. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(65.335-0)/8.631
=7.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharma Equity Group AS  (OCSE:PEG) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Pharma Equity Group AS Quick Ratio Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group AS's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group AS Business Description

Traded in Other Exchanges
N/A
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .